DUNCAN BARBARA GAYLE 4

What Happened

• Barbara Gayle Duncan, a director of Ovid Therapeutics, received a grant of 65,000 derivative shares (reported as an award/acquisition) on February 26, 2026. The reported price per share is $0.00 and the filing shows the instrument as a derivative; the reported aggregate cash value is $0.
• The award is subject to a vesting condition: it will vest in full on February 26, 2027, contingent on Duncan’s continuous service through that date. Because it’s a time‑vesting derivative award, no shares were immediately sold or transferred.

Key Details

• Transaction date: 2026-02-26; Form 4 filed: 2026-03-02 (timely filing).
• Transaction type/code: A (Grant/Award/Other acquisition) — derivative security.
• Quantity: 65,000 shares; reported price: $0.00; reported cash value: $0.
• Vesting note: F1 — “The option will vest in full on February 26, 2027, subject to the Reporting Person's continuous service through such vesting date.”
• Shares owned after transaction: not specified in the provided filing excerpt.

Context

• This is a compensation grant (derivative award) that vests in one year; it does not represent an immediate open‑market purchase or sale. Such awards are commonly used as part of director or executive compensation and do not, by themselves, indicate an immediate change in insider holdings or intent to trade.